Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
JIB
GLOBETECH PUBLISHING

High GABA Level Astrocytes Are a New Alzheimer's Disease Biomarker and Drug Target

By BiotechDaily International staff writers
Posted on 25 Jun 2014
Image: This image shows a microscopic view of the high concentration (red) of gamma-aminobutyric acid (GABA) in the reactive astrocytes (green) in the human brain with Alzheimer\'s disease (Photo courtesy of Dr. Gong Chen, Pennsylvania State University).
Image: This image shows a microscopic view of the high concentration (red) of gamma-aminobutyric acid (GABA) in the reactive astrocytes (green) in the human brain with Alzheimer\'s disease (Photo courtesy of Dr. Gong Chen, Pennsylvania State University).
Cells comprising an abnormal class of brain cells called reactive astrocytes contain high levels of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) and are being eyed by researchers as a potential biomarker and drug target for Alzheimer's disease (AD).

Amyloid plaques and tau tangles are common pathological characteristics of AD. However, drugs designed to reduce production of the Abeta peptides that form amyloid plaques failed to relieve the symptoms of AD patients. Now, a paper published the June 13, 2014, online edition of the journal Nature Communications reported the presence of high GABA content in reactive astrocytes in the dentate gyrus (DG) of a mouse model for AD that resulted in increased tonic inhibition and memory deficit.

Investigators at Pennsylvania State University (University Park, USA) also confirmed the presence of astrocytes with a high GABA content in human AD patient brains. This finding suggested that a high astrocytic GABA level may be a novel biomarker and a potential diagnostic tool for AD.

They also considered the possibility of developing drugs to target these high GABA level astrocytes after it was found that excessive GABA was released through an astrocyte-specific GABA transporter (GAT3/4).

"Our studies of AD mice showed that the high concentration of the GABA neurotransmitter in the reactive astrocytes of the dentate gyrus correlates with the animals' poor performance on tests of learning and memory," said senior author Dr. Gong Chen, professor of biology at Pennsylvania State University. "After we inhibited the astrocytic GABA transporter to reduce GABA inhibition in the brains of the AD mice, we found that they showed better memory capability than the control AD mice. We are very excited and encouraged by this result because it might explain why previous clinical trials failed by targeting amyloid plaques alone. One possible explanation is that while amyloid plaques may be reduced by targeting amyloid proteins, the other downstream alterations triggered by amyloid deposits, such as the excessive GABA inhibition discovered in our study, cannot be corrected by targeting amyloid proteins alone. Our studies suggest that reducing the excessive GABA inhibition to the neurons in the brain's dentate gyrus may lead to a novel therapy for Alzheimer's disease. An ultimate successful therapy may be a cocktail of compounds acting on several drug targets simultaneously."

Related Links:

Pennsylvania State University 



comments powered by Disqus

Channels

Drug Discovery

view channel
Image: S-649266 has more robust antibacterial activity than established antibiotics against multidrug-resistant bacteria (Photo courtesy of Shionogi).

Novel Antibiotic Shows Potential for Broad Range of Infections

The emergence of bacterial resistance to known antibacterial agents is becoming a major challenge in treating the infection caused by multi drug resistant (MDR) bacteria. In order to treat bacterial... Read more

Business

view channel

Collaboration of Mayo Clinic and IBM Cognitive Computer Devised to Improve Clinical Trial Research

The Mayo Clinic (Rochester, MN, USA) and IBM (Armonk, NY, USA) recently announced plans to pilot Watson, the IBM cognitive computer, to match patients more rapidly with suitable clinical trials. A proof-of-concept phase is currently ongoing, with the intent to introduce it into clinical use in early 2015.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.